 | Up a level |
Rotger, M; Tegude, H; Colombo, S; Cavassini, M; Furrer, H; Décosterd, L; Blievernicht, J; Saussele, T; Günthard, H F; Schwab, M; Eichelbaum, M; Telenti, A; Zanger, U M (2007). Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals. Clinical pharmacology & therapeutics, 81(4), pp. 557-66. New York, N.Y.: Nature Publishing Group 10.1038/sj.clpt.6100072
Rotger, M; Taffe, P; Bleiber, G; Gunthard, HF; Furrer, H; Vernazza, P; Drechsler, H; Bernasconi, E; Rickenbach, M; Telenti, A; Swiss, HIV Cohort Study (2005). Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. Journal of infectious diseases, 192(8), pp. 1381-6. Cary, N.C.: The University of Chicago Press 10.1086/466531
Colombo, S; Soranzo, N; Rotger, M; Sprenger, R; Bleiber, G; Furrer, H; Buclin, T; Goldstein, D; Décosterd, L; Telenti, A; Swiss, HIV Cohort Study (2005). Influence of ABCB1, ABCC1, ABCC2, and ABCG2 haplotypes on the cellular exposure of nelfinavir in vivo. Pharmacogenetics and genomics, 15(9), pp. 599-608. London: Lippincott Williams & Wilkins 10.1097/01.fpc.0000172241.42546.d3
Rotger, M; Colombo, S; Furrer, H; Bleiber, G; Buclin, T; Lee, BL; Keiser, O; Biollaz, J; Décosterd, L; Telenti, A; Swiss, HIV Cohort Study (2005). Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenetics and genomics, 15(1), pp. 1-5. London: Lippincott Williams & Wilkins
Tarr, PE; Taffé, P; Bleiber, G; Furrer, H; Rotger, M; Martinez, R; Hirschel, B; Battegay, M; Weber, R; Vernazza, P; Bernasconi, E; Darioli, R; Rickenbach, M; Ledergerber, B; Telenti, A; Swiss, HIV Cohort Study (2005). Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders. Journal of infectious diseases, 191(9), pp. 1419-26. Cary, N.C.: The University of Chicago Press 10.1086/429295
